StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho Sees Potential Nektar Therapeutics (NKTR) Takeover by Bristol-Myers Squibb (BMY) This Year
March 2, 2018 6:31 AM
Mizuho Securities analyst Difei Yang believes there is a possibility of a Nektar Therapeutics (NASDAQ: NKTR) take-out in 2018 and ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Rumors
Next Articles
Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at BofA/Merrill Lynch on Increased Confidence of Opdivo/Yervoy Approvability
March 5, 2018 9:19 AM
Nektar Therapeutics (NKTR) PT Raised to $63 at Evercore ISI; 'Highlights from 4Q earnings call'
March 2, 2018 1:34 AM
Nektar Therapeutics (NKTR) PT Raised to $103 at Jefferies
March 2, 2018 1:01 AM
Form 8-K NEKTAR THERAPEUTICS For: Mar 01
March 1, 2018 6:06 PM
Nektar Therapeutics (NKTR) Reports Q4 Loss of $0.21
March 1, 2018 4:28 PM